Your session is about to expire
← Back to Search
Dual Drug Therapy for NASH with Fibrosis (MIRNA Trial)
MIRNA Trial Summary
This trial is testing two new drugs to see if they can improve non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).
MIRNA Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMIRNA Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 75 Patients • NCT04399538MIRNA Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have liver conditions like alcoholic liver disease, cirrhosis, or active hepatitis.I do not have any unstable health conditions like heart issues or liver problems.My liver condition is confirmed as NASH with moderate to severe scarring.You must have a body mass index (BMI) of 22.5 kg/m2 or higher.You need to have a body mass index (BMI) of 22.5 or higher.Your body mass index (BMI) should be equal to or greater than 22.5kg/m2.I have a condition that might affect how my body absorbs medication.
- Group 1: Placebo
- Group 2: PF-06865571 75 mg BID
- Group 3: PF-06865571 25 milligrams (mg) twice daily (BID)
- Group 4: PF-06865571 (150 mg BID) + PF-05221304 (5 mg BID)
- Group 5: PF-06865771 (300 mg BID) + PF-05221304 (10 mg BID)
- Group 6: PF-06865571 300 mg BID
- Group 7: PF-06865571 150 mg BID
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the regulatory agency cleared PF-06865571 for use?
"Given the Phase 2 state of this drug, there is evidence that it is safe but no indication yet as to its efficacy. Therefore, our team has assigned a score of two out of three in terms of safety."
Does the criteria for entry into this research include individuals aged twenty or younger?
"This study is open to any patients aged 18-75. Patients under the age of 18 can take part in 107 other trials and those over 65 have access to 685 different studies."
Is this medical research recruiting participants at the present time?
"This clinical investigation is not presently recruiting participants, as evident on the information posted in clinicaltrials.gov from June 15th 2020 to November 17th 2022. However, there are currently 766 other medical studies that are looking for volunteers at this exact moment."
Is it possible to become a participant in this experimental investigation?
"To partake in this trial, participants must have fibrosis and range between 18-75 years old. Currently, an estimated 231 persons are taking part."
Are there any research centers carrying out this experiment in North America?
"This medical trial is enrolling a total of 100 patients, some from MUSC Investigational Drug Pharmacy in Charleston, TGH Imaging Powered by Tower Radiology Center (MRI) in Oldsmar and Icahn School of Medicine at Mount Sinai/The Mount Sinai Hospital in New york. There are many other participating clinical sites as well."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
How responsive is this trial?
Typically responds via
Share this study with friends
Copy Link
Messenger